The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Exploring novel SCCA treatments: CD4 vaccine + checkpoint inhibitor
Stefano Kim, MD, Centre Hospitalier Universitaire de Besançon, Besançon, France, discusses the exploration of novel treatments for squamous cell anal carcinoma (SCCA). His team is evaluating a universal tumor vaccine, specifically a CD4 human telomerase vaccine, in combination with a checkpoint inhibitor. The results so far are encouraging, and they are considering the future use of this treatment, possibly as a first-line maintenance treatment for patients without a complete response. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
